

Supplementary Materials




FIGURE S1: Immunophenotype of RA MSCs. Culture-expanded MSCs are comprised of a homogenous cell population positive for CD166, CD105, CD44, CD73 and negative for CD14, CD34, CD45, CD31 surface markers. The blue and red histograms depict the negative and positive markers respectively. Isotype control staining is represented by the black histograms.




FIGURE S2: Differentiation potential of RA MSCs. (A) MSCs from controls (a) and RA patients (b) differentiated into osteoblasts (Alizarin red staining, magnification $\times 200$). (B) MSCs from controls (c) and RA patients (d) differentiated into adipocytes (Oil Red O staining, magnification $\times 200$). The figure shows one representative results from three independent experiments. (C-D) mRNA expression levels of the osteogenic marker *Runx2* and the adipogenic marker *PPARγ* on day 21 after osteogenic and adipogenic induction (n=3 for control MSCs and RA MSCs). n.s., no significant difference. *Runx2*, runt-related transcription factor 2; *PPARγ*, peroxisome proliferator-activated receptor gamma.




FIGURE S3: No significant correlation between DAS28 in RA patients with CCL2 expression in RA MSCs after co-culture. DAS28, disease activity score in 28 joints.




FIGURE S4: Isotype control staining of CD25, FoxP3, CXCR5 and PD-1.

| | A | B | C | D | E | F | G | H | I | J | K | L | M | N |
|----|---------|--------|-------|-------|--------|----------------|----------------|---------------|--------------|----------------|-------------------|--------|--------|--------|
| 1 | POS1 | POS2 | POS3 | NEG | NEG | ANG | BDNF | BLC | BMP4 | BMP6 | $\alpha\beta$ 8-1 | CNTF | EGF | CCL11 |
| 2 | POS1 | POS2 | POS3 | NEG | NEG | ANG | BDNF | BLC | BMP4 | BMP6 | $\alpha\beta$ 8-1 | CNTF | EGF | CCL11 |
| 3 | CCL24 | CCL26 | FGF6 | FGF7 | Flt-3L | CX3CL1 | GCP-2 | GDNF | CSF2 | I-309 | IFN- γ | IGFBP1 | IGFBP2 | IGFBP4 |
| 4 | CCL24 | CCL26 | FGF6 | FGF7 | Flt-3L | CX3CL1 | GCP-2 | GDNF | CSF2 | I-309 | IFN- γ | IGFBP1 | IGFBP2 | IGFBP4 |
| 5 | IGF-1 | IL-10 | IL-13 | IL-15 | IL-16 | IL-1 α | IL-1 β | IL-1 α | IL-2 | IL-3 | IL-4 | IL-5 | IL-6 | IL-7 |
| 6 | IGF-1 | IL-10 | IL-13 | IL-15 | IL-16 | IL-1 α | IL-1 β | IL-1 α | IL-2 | IL-3 | IL-4 | IL-5 | IL-6 | IL-7 |
| 7 | Lepin | LIGHT | MCP1 | MCP2 | MCP3 | MCP4 | M-CSF | MDC | MIG | MIP-1 δ | MIP-3 α | NAP-2 | NT-3 | PARC |
| 8 | Lepin | LIGHT | MCP1 | MCP2 | MCP3 | MCP4 | M-CSF | MDC | MIG | MIP-1 δ | MIP-3 α | NAP-2 | NT-3 | PARC |
| 9 | PDGF-BB | RANTES | SCF | SDF-1 | TARC | TGF- β 1 | TGF- β 3 | TNF- α | TNF- β | NEG | NEG | NEG | NEG | NEG |
| 10 | PDGF-BB | RANTES | SCF | SDF-1 | TARC | TGF- β 1 | TGF- β 3 | TNF- α | TNF- β | NEG | NEG | NEG | NEG | NEG |

FIGURE S5: Cytokines for each dot in the protein array.

TABLE S1: C reactive protein (CRP) levels of osteoarthritis patients used in this study.

| Patient | CRP (mg/L) |
|---------|---------------|
| 1 | 1.2 |
| 2 | 1.5 |
| 3 | 2.6 |
| 4 | 1.8 |
| 5 | 5.5 |
| 6 | 1.7 |